DarioHealth Q2 2026 earnings: Margin expands despite lower revenue

DarioHealth (NASDAQ: DRIO) reported Q2 2026 revenue of $5.2 million, down from $5.4 million a year earlier, while GAAP diluted loss per share narrowed to $0.85 from $3.54. Gross margin expanded to 61.7%, and lower operating expenses helped reduce the operating loss by 30% year over year despite the revenue decline.

Core financial results

Revenue declined as DarioHealth moved away from one-time pharmaceutical services, partly offset by growth in enterprise B2B2C revenue and direct-to-consumer sales. Improved product mix, lower cost of revenue and an IEEPA tariff refund lifted gross profit even as total revenue decreased.

Cost reductions were also material. Operating expenses fell 21% to $9.7 million, resulting in narrower GAAP and non-GAAP operating losses.

The per-share comparison also reflects a prior-year deemed dividend and a substantially higher weighted-average share count in Q2 2026, so the EPS improvement was larger than the underlying reduction in operating loss.

Business and revenue mix

DarioHealth’s reported revenue categories moved in opposite directions. Services revenue fell approximately 29% to $2.585 million from $3.661 million, reflecting the absence of prior-year pharmaceutical services revenue. Consumer hardware revenue increased approximately 52% to $2.592 million from $1.708 million.

The company reported $13.1 million of contracted and late-stage annual recurring revenue, more than 80% of which involved multiple conditions. This figure combines contracted opportunities with late-stage pipeline and should not be treated as revenue already recognized.

Recent commercial activity included several customer expansions and additions:

• A top-five national health plan extended its behavioral health agreement and added DarioHealth’s hypertension solution. The company said the expansion could approximately triple the potential revenue opportunity within that relationship, with some contribution expected in 2026 and a greater impact from 2027.
• Solera added DarioHealth’s hypertension program for more than 500,000 additional eligible lives, approximately doubling the addressable eligible population through that channel.
• A fifth Fortune 50 client, representing more than 100,000 eligible employees, is expected to begin contributing ARR near the end of 2026 and ramp during 2027.
• DarioHealth also added a health insurer through its Amwell partnership and expanded into provider-backed care through Beluga Health’s clinical infrastructure.

The new Dario Women and Dario Sleep programs are expected to begin contributing revenue in Q4 2026. No amount of expected revenue was disclosed.

Commercial momentum has not yet translated into revenue growth

The central issue in Q2 was the gap between reported revenue and the company’s commercial pipeline. Quarterly revenue declined both year over year and from $5.6 million in Q1 2026, while several recent customer wins are not expected to contribute until late 2026 or 2027.

DarioHealth’s multi-condition strategy could raise revenue per customer without equivalent acquisition spending, particularly when existing health-plan and channel relationships add new conditions. Provider-backed care could further expand the services offered through each account. However, the financial effect will depend on implementation schedules, enrollment, utilization and the conversion of late-stage opportunities into contracted revenue.

Profitability, cash flow and balance sheet

Gross margin improved by 6.5 percentage points year over year and 4.4 percentage points sequentially. Management attributed the increase to product mix, lower cost of revenue and a tariff refund recognized during the quarter. Because the refund contributed to the result, investors will need to distinguish that benefit from sustainable improvements in mix and underlying costs.

Expense reductions were broad. Research and development expense fell to $2.1 million from $3.7 million, sales and marketing declined to $5.0 million from $5.2 million, and general and administrative expense decreased to $2.6 million from $3.2 million. Management also said its use of AI internally helped expand operating capabilities while holding down the cost base.

DarioHealth disclosed cash flow only for the first six months of 2026. Net cash used in operating activities was $12.108 million, compared with $12.704 million in the first half of 2025. At June 30, the company held approximately $14.0 million in cash, cash equivalents and short-term deposits and reported a $31.064 million long-term loan.

After quarter-end, DarioHealth raised $22.8 million net through a registered direct financing. Including those proceeds, pro forma cash, cash equivalents and short-term deposits were $36.8 million. The financing improved liquidity but also involved the issuance of additional equity.

Management perspective

CEO Erez Raphael said DarioHealth’s multi-condition platform, enterprise distribution and AI capabilities are creating opportunities to generate more recurring revenue from existing customers. Management believes the provider-backed care expansion can give the company access to a larger portion of the healthcare value chain and expects revenue growth to accelerate by the end of 2026 and into 2027.

The company also believes broader deployment of DarioIQ could increase B2B2C ARR from existing customers by 10% to 15% through improved engagement, retention and clinical outcomes. This is a management estimate rather than reported financial performance.

Risks investors need to watch

• Revenue remains under pressure: The transition away from pharmaceutical services reduced Q2 revenue, while newer enterprise contracts have not yet produced enough contribution to restore growth.
• Pipeline conversion and timing: The $13.1 million figure includes both contracted and late-stage ARR. Delays in implementation or failure to convert pipeline opportunities could push out expected revenue.
• Continued operating losses: Although expenses and losses declined, the company still recorded a $6.5 million quarterly operating loss on $5.2 million of revenue.
• Margin sustainability: Q2 gross margin benefited partly from a tariff refund whose amount was not separately disclosed, making the recurring level of improvement less certain.
• Cash consumption and financing: First-half operating cash use remained $12.1 million. The July equity financing strengthened liquidity but raises dilution considerations, while the company continues to carry a $31.1 million long-term loan.

Summary

DarioHealth’s Q2 2026 results showed better gross margin, lower expenses and narrower losses, but revenue continued to decline as the company exited pharmaceutical-related work. The next phase depends on whether recent multi-condition customer expansions, channel wins and provider-backed offerings begin producing recurring revenue on the expected late-2026 and 2027 timelines while the company maintains cost discipline and manages cash consumption.